Tesamorelin Dosing Guide: GHRH Analogue Research Protocols, Reconstitution and Clinical Evidence

Tesamorelin is the only growth hormone releasing hormone (GHRH) analogue ever approved by the FDA for human use. Greenlit in 2010 under the brand name Egrifta, it stimulates the pituitary to release endogenous growth hormone in physiological, pulsatile patterns rather than flooding the body with exogenous human growth hormone (HGH). The research community continues to investigate the compound two decades after its discovery, and this guide compiles the clinical evidence, reconstitution math, subcutaneous administration protocol and comparison data needed to work with Tesamorelin for research purposes.

The target audience for this article is narrow on purpose: researchers, clinicians and peptide science enthusiasts who already understand subcutaneous injection, milligram and international unit (IU) conversions, and the regulatory status of experimental peptides. Every section assumes that baseline. If you are new to peptide research, our Selank dosing guide and Semax dosing guide cover the foundational framework of GMP sourcing, vial handling and research protocol design.

What is Tesamorelin?

Tesamorelin (research code TH9507, trade name Egrifta) is a 44 amino acid synthetic analogue of human growth hormone releasing hormone, or hGHRH(1-44). Its defining structural feature is an N-terminal trans-3-hexenoic acid modification, a short unsaturated fatty acid attached to the amino terminus that shields the peptide from rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV). Native GHRH has a plasma half life of only a few minutes because DPP-IV cleaves the first two residues on contact. The hexenoyl cap roughly triples the plasma persistence of Tesamorelin without altering its receptor binding profile.

The molecular weight is approximately 5135.9 Da, the Chemical Abstracts Service number is CAS 218949-48-5, and the amino acid sequence corresponds to native GHRH(1-44): H-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2, with the trans-3-hexenoyl group on the N-terminal residue.

The compound was developed by the Canadian biotech Theratechnologies and received FDA approval on 10 November 2010 for the reduction of excess visceral adipose tissue (VAT) in HIV-infected patients with lipodystrophy. The European Medicines Agency granted centralized approval in July 2011, but marketing authorization was withdrawn at the request of the sponsor in 2014 for commercial reasons (not safety). Egrifta remains the first and only FDA-approved GHRH analogue, and HIV-associated lipodystrophy remains its sole approved indication worldwide.

Outside of that labeled indication, Tesamorelin has been studied for age-related somatopause, non-alcoholic fatty liver disease (NAFLD), mild cognitive impairment and metabolic syndrome. None of those investigational uses are approved. In most jurisdictions Tesamorelin sold as a lyophilized research chemical is legal to purchase for laboratory research but not for human use, and this article treats it strictly as a research compound.

Mechanism of action

Tesamorelin is a selective agonist at the GHRH receptor (GHRHR), a class B G protein-coupled receptor expressed predominantly on somatotroph cells in the anterior pituitary. Binding activates adenylate cyclase through Gs alpha coupling, elevating intracellular cyclic AMP and triggering the release of stored growth hormone (GH) from secretory granules. The released GH then acts systemically, most importantly on hepatocytes, where it induces insulin-like growth factor 1 (IGF-1) synthesis via JAK2 / STAT5 signaling.

Because Tesamorelin works upstream of the pituitary rather than replacing GH directly, the resulting GH profile preserves the body's natural negative feedback. Somatostatin tone, sleep-wake cycles and metabolic signals (glucose, free fatty acids) continue to modulate the amplitude and frequency of GH pulses. The clinical consequence is an IGF-1 elevation that stays within the age-appropriate physiological reference range in properly dosed subjects, rather than the supraphysiological IGF-1 levels often seen with exogenous HGH administration.

In Theratechnologies' Phase 3 program the primary pharmacodynamic effect of daily 2 mg Tesamorelin was a selective reduction of visceral adipose tissue. Over 26 weeks, treated HIV lipodystrophy patients lost an average of 15 to 18 percent of their VAT, with concurrent improvements in triglycerides, total cholesterol, and the adiponectin to leptin ratio. Subcutaneous fat and lean mass were preserved or modestly improved.

Why pulsatile GH release outperforms supraphysiological dosing

Exogenous HGH raises circulating GH in a flat, non-pulsatile pattern that the body has not evolved to process. Chronic flat GH exposure saturates hepatic IGF-1 production, desensitizes peripheral GH receptors, and drives water retention, carpal tunnel syndrome and insulin resistance at higher frequencies than pulsatile signaling does. Tesamorelin restores the natural pulse architecture: sharp peaks one to three hours after injection, baseline troughs in between, and cumulative 24 hour GH exposure that sits near the upper end of the healthy physiological window rather than above it. That pattern is the rationale for the compound's relatively mild side effect profile in controlled trials.

Pharmacokinetics and half-life

Following subcutaneous injection of 2 mg in the abdominal wall, Tesamorelin reaches peak plasma concentration within 15 minutes and the parent peptide has a plasma elimination half life of roughly 26 to 38 minutes, depending on body composition and injection site. The short circulating half life is intentional. A single sharp exposure is all that is needed to trigger the somatotroph release of pre-formed GH, and the downstream effects persist long after the peptide itself has been cleared.

The pharmacodynamic cascade is much longer than the pharmacokinetic one. GH peaks in the systemic circulation approximately one to two hours post injection. Hepatic IGF-1 synthesis then ramps up, with circulating IGF-1 elevations measurable 12 to 24 hours after a single dose and steady state reached after roughly 14 days of daily dosing. The fat-redistribution effect on visceral adipose tissue becomes detectable on abdominal CT scans after approximately 8 weeks and plateaus between 26 and 52 weeks of continuous administration.

Tesamorelin is catabolized by standard peptidase activity into inactive amino acid fragments. There is no CYP450 interaction, no meaningful renal excretion of intact peptide, and no accumulation with daily dosing.

Research evidence

The pivotal efficacy evidence comes from two identically designed Phase 3 randomized placebo-controlled trials run by Theratechnologies and reported by Julian Falutz and colleagues in the New England Journal of Medicine in 2007 (Falutz et al., NEJM 357:2359-2370). The combined enrollment of 816 HIV lipodystrophy patients received either 2 mg Tesamorelin SC daily or placebo for 26 weeks. The treatment arm achieved an 18 percent mean reduction in visceral adipose tissue versus a small increase in placebo, with statistically significant improvements in triglycerides (minus 50 mg/dL), total cholesterol, and patient-reported body image. Adverse events were mild and reversible. These studies formed the basis of the 2010 FDA approval.

The follow-on open-label extension published by Steven Grinspoon and colleagues in 2010 and 2012 confirmed that the VAT reduction was maintained through 52 weeks of continuous dosing and that patients who switched from placebo to active compound at week 26 caught up to the original treatment arm by week 52. Discontinuation reversed the benefit within six months, establishing that Tesamorelin does not cure lipodystrophy. It manages it.

Outside the approved indication, the most interesting signal came from the Baker et al. 2012 Archives of Neurology study that tested Tesamorelin in older adults with and without mild cognitive impairment. Twenty weeks of daily Tesamorelin produced statistically significant improvements in executive function, verbal memory and working memory, accompanied by changes in cerebrospinal fluid neurotransmitter concentrations. Subsequent MRI spectroscopy work by the same group documented favorable shifts in brain metabolite ratios. These findings remain exploratory but have sustained research interest in GHRH agonism as a pro-cognitive mechanism.

Additional work has examined Tesamorelin in non-alcoholic fatty liver disease, where a 2019 Stanella et al. randomized trial in HIV-positive adults with NAFLD showed significant reductions in hepatic fat fraction on MRI. Investigator-initiated studies on abdominal adiposity in non-HIV populations, post-traumatic stress disorder, and age-related metabolic decline are ongoing or have been published in small cohorts, none of which have produced an approved expansion of the indication.

Research dosing protocols

The clinically validated dose is 2 mg Tesamorelin subcutaneously once daily. This is the dose studied in every FDA registration trial and the dose carried forward in long term extension work. Research protocols in non-HIV populations have used the same 2 mg per day reference, with a small number of exploratory designs testing 1 mg per day for subjects with lower body mass or concerns about IGF-1 excursions.

Upward titration above 2 mg per day has no evidence base. Doses of 3 to 4 mg have been tried in early Phase 1 work but produced disproportionate increases in side effects (edema, arthralgia, glucose intolerance) without additional efficacy. The GHRH receptor population on somatotrophs appears to saturate near 2 mg, after which further dose increases no longer proportionally increase GH pulse amplitude.

A typical research cycle runs 12 to 26 weeks of continuous daily dosing, followed by a washout period of at least 8 weeks. Cycling rather than year-round dosing is the norm in non-label research settings because extended daily administration can progressively attenuate GH pulse amplitude through receptor desensitization and because the lipolytic and cognitive benefits plateau well before 52 weeks.

If a dose is missed, research protocols generally instruct subjects to skip that day rather than double-dose the next. Because the pharmacodynamic effect persists 24 to 48 hours, a single missed dose has negligible impact on IGF-1 steady state.

Why bedtime dosing is preferred

Endogenous GH secretion in healthy adults is tightly tied to sleep architecture, with the largest spontaneous pulse occurring within the first 60 to 90 minutes of slow wave sleep. Dosing Tesamorelin approximately 30 minutes before bedtime aligns the exogenously triggered GH pulse with this natural window, amplifying the body's own signal rather than competing with it. Daytime dosing still produces a GH peak, but the peak is partially blunted by tonic somatostatin, circulating glucose and amino acid fluxes from meals. An empty stomach at the time of injection (no food for two hours prior, carbohydrates especially) measurably increases the magnitude of the GH response.

Reconstitution and subcutaneous administration

Tesamorelin ships as a sterile lyophilized powder in amber glass vials of 10 mg or 20 mg peptide content, filled under nitrogen atmosphere. The reconstitution diluent is bacteriostatic water for injection (BAC water), a water solution containing 0.9 percent benzyl alcohol as a preservative. Benzyl alcohol extends the usable life of the reconstituted solution to approximately 14 days at 2 to 8 degrees Celsius. BAC water is available separately and is part of the standard research setup alongside the peptide itself.

For a 10 mg vial, the standard reconstitution choices are:

10 mg + 1 mL BAC water yields a concentration of 10 mg/mL, or equivalently 10000 mcg/mL. On a U100 insulin syringe (where 100 IU equals 1 mL), a 2 mg dose corresponds to 0.2 mL, which reads as 20 IU on the U100 scale. Math: 2 mg divided by 10 mg/mL equals 0.2 mL equals 20 IU.

10 mg + 2 mL BAC water yields a concentration of 5 mg/mL, or 5000 mcg/mL. A 2 mg dose corresponds to 0.4 mL, which reads as 40 IU on the U100 scale. Math: 2 mg divided by 5 mg/mL equals 0.4 mL equals 40 IU.

The 2 mL reconstitution is generally preferred by researchers because the larger injection volume reduces the risk of dosing error, spreads the depot over a slightly wider subcutaneous footprint, and the 40 IU mark sits in the well-graduated middle of the U100 scale. The 1 mL reconstitution concentrates the solution and is useful when injection discomfort from larger volumes is a concern.

Before reconstitution, the lyophilized vial must be stored at 2 to 8 degrees Celsius in its original packaging, protected from light, from receipt through injection. Once reconstituted, the solution must be kept refrigerated at the same 2 to 8 degrees Celsius and discarded after 14 days regardless of apparent clarity. Never freeze the solution, never shake the vial during reconstitution, and never use a vial that shows visible particulates, cloudiness or discoloration.

Step by step injection procedure

The standard equipment is a 29 or 30 gauge U100 insulin syringe with an integrated 4 to 8 mm needle. Our product listing for the BD MICRO-FINE+ 0.5 mL U100 30G x 8 mm insulin syringe is the syringe used throughout this protocol. For companion supplies including BD pen needles, U40 insulin syringes and other injection equipment, see our diabetes supplies collection.

Procedure:

1. Remove the reconstituted Tesamorelin vial from the refrigerator 5 minutes before injection to reduce local discomfort.

2. Wipe the vial rubber stopper with a sterile wipe and allow it to dry.

3. Draw the target volume into the U100 insulin syringe. For 2 mg from a 10 mg + 2 mL preparation, draw exactly to the 40 IU mark. Tap out any air bubbles and reset the plunger to the mark.

4. Select a subcutaneous site in the abdominal fat pad, at least 2 cm lateral to the umbilicus. Rotate sites daily around the abdomen, upper thigh or outer deltoid to prevent lipohypertrophy.

5. Pinch a subcutaneous fold and insert the needle at 90 degrees for an 8 mm needle and subcutaneous fat thickness above 6 mm, or at 45 degrees for thinner fat pads.

6. Inject slowly over 3 to 5 seconds. Do not aspirate; the short needle length rules out intravascular placement risk.

7. Release the pinch, withdraw the needle, and apply light pressure with a sterile gauze. Do not rub the site.

8. Discard the syringe into a rigid sharps container. Never reuse insulin syringes.

Tesamorelin vs Ipamorelin / CJC-1295

Tesamorelin, Ipamorelin and CJC-1295 all raise circulating GH, but they do so through different receptor systems, and the resulting pharmacology is meaningfully different.

Receptor target. Tesamorelin binds the GHRH receptor. Ipamorelin binds the ghrelin receptor (GHSR-1a) as a selective growth hormone secretagogue (GHS). CJC-1295 is itself a GHRH analogue, binding the same receptor as Tesamorelin but with a drug affinity complex (DAC) linker that extends its half life to roughly 6 to 8 days rather than 30 minutes.

GH pulse architecture. Tesamorelin produces a sharp, short GHRH mediated pulse every time it is injected, mimicking physiological pulsatility. Ipamorelin produces a similarly sharp pulse but via a different intracellular signaling cascade that does not elevate cortisol, prolactin or ACTH (unlike older GHS such as GHRP-6). CJC-1295 with DAC produces a sustained, flat elevation of basal GH output that is more HGH-like than GHRH-like, which is why it is often combined with a short acting GHS to reintroduce pulses.

Dose and frequency. Tesamorelin is dosed 2 mg SC once daily at bedtime. Ipamorelin is typically dosed 100 to 300 mcg SC two or three times daily. CJC-1295 with DAC is dosed once or twice weekly at 1 to 2 mg. Tesamorelin carries the only FDA approval in this group; the others are research compounds with no human regulatory approval anywhere in the world.

Evidence base. Tesamorelin has Phase 3 randomized controlled trial data supporting efficacy in VAT reduction and safety through 52 weeks of daily dosing. Ipamorelin and CJC-1295 have only Phase 1 safety and tolerability data plus decades of off-label bodybuilding community reports; no Phase 3 program has ever been run for either compound.

Stacking. Because Tesamorelin and Ipamorelin activate different receptors, they are often combined in non-label research protocols to produce larger summed GH pulses than either alone. Tesamorelin plus CJC-1295 combines two agonists of the same receptor and does not produce meaningful additive effect.

Side effects and safety profile

Across the combined Phase 3 Tesamorelin database of over 800 treated subjects, the most frequently reported adverse events were injection site reactions (erythema, pruritus, small local hematoma) at roughly 25 percent of subjects, arthralgia and myalgia at 10 to 15 percent, and peripheral edema at 6 to 8 percent. Most of these were mild, most resolved without intervention within the first 4 to 8 weeks of dosing, and fewer than 5 percent of subjects discontinued for adverse events.

The clinically significant long-term concern is glucose metabolism. Because GH antagonizes insulin at the hepatic and peripheral level, daily GHRH stimulation can modestly elevate fasting glucose and HbA1c over 26 to 52 weeks. In the Phase 3 database, the mean HbA1c increase was approximately 0.1 to 0.2 percent at 52 weeks, clinically minor for most subjects but relevant for anyone with pre-existing insulin resistance or type 2 diabetes. Monitoring of fasting glucose and HbA1c every 12 weeks during a research cycle is standard.

IGF-1 excursions above the age-adjusted reference range have been reported in roughly 15 percent of subjects on 2 mg daily dosing. Sustained IGF-1 elevation is a theoretical concern for occult malignancy and for proliferative retinopathy, and most research protocols include a baseline and a 12 week IGF-1 measurement with dose reduction or discontinuation triggers at greater than 2 standard deviations above the age-matched mean.

Contraindications include known hypersensitivity to mannitol (present in the formulation), active malignancy, pregnancy, disruption of the hypothalamic-pituitary axis (after surgery, radiation or major trauma), and severe hypersensitivity to any component of the lyophilized product. Concomitant use of systemic glucocorticoids reduces Tesamorelin efficacy by suppressing the pituitary GH response.

Sourcing and quality markers

Tesamorelin sold as a research chemical is widely available, but the quality of the peptide varies substantially between suppliers. For injectable research peptides, four quality markers matter: chromatographic purity, identity confirmation, endotoxin content, and sterility.

Purity should be documented by high-performance liquid chromatography (HPLC) at a minimum of 98 percent, with better suppliers targeting greater than 99 percent. The certificate of analysis (CoA) should include the HPLC chromatogram, not just a headline figure. Identity should be confirmed by mass spectrometry matching the expected 5135.9 Da molecular weight. Endotoxin, typically measured by the Limulus amebocyte lysate (LAL) assay, should be under 5 endotoxin units per mg of peptide; injectable peptides with elevated endotoxin produce sterile pyrogenic reactions at the injection site and should not be used.

Commercial research suppliers typically offer Tesamorelin in 10 mg and 20 mg lyophilized vials. For the German and European research market, Bergdorf Bio is a frequently cited source; they list COA-zertifiziertes Tesamorelin von Bergdorf Bio with published HPLC data on each lot. Their catalog also includes the bacteriostatic water for research reconstitution that pairs with the lyophilized peptide. For labs that prioritize published chromatograms alongside the vial, the same supplier's HPLC-verified Tesamorelin lot documentation is one reasonable reference point.

Shipping should be on cold packs or dry ice with documented chain-of-custody temperature, because lyophilized peptides tolerate brief excursions to ambient but should not be exposed to prolonged warmth. A vial that arrives warm to the touch should be returned to the supplier.

Frequently asked questions

What is the typical research dose of Tesamorelin?

2 mg subcutaneously once daily, dosed at bedtime, for a 12 to 26 week cycle. This is the FDA-registered dose and the dose used in every published Phase 3 study.

Why is Tesamorelin injected subcutaneously rather than taken orally?

The 44 amino acid peptide would be completely hydrolyzed by gastric pepsin and intestinal proteases if swallowed. Bioavailability of oral Tesamorelin is effectively zero. Intranasal delivery is similarly infeasible for a peptide of this molecular weight; the nasal mucosa does not transport molecules above roughly 1000 Da efficiently. Subcutaneous injection is the only route that achieves reproducible systemic exposure.

How long does a 10 mg vial last at the reference dose?

At 2 mg per day, a 10 mg vial covers 5 days of research. However, the reconstituted solution is stable for approximately 14 days at 2 to 8 degrees Celsius. A 10 mg vial reconstituted today will expire with unused peptide remaining if the cycle pauses, which is why many protocols stock multiple 10 mg vials rather than a single 20 mg vial.

What is the plasma half-life?

The parent peptide has a circulating half-life of 26 to 38 minutes. The downstream GH pulse peaks at one to two hours and the IGF-1 elevation lasts 24 hours or longer, which is why once daily dosing produces steady-state effects.

How does Tesamorelin differ from exogenous HGH?

HGH is the terminal hormone; Tesamorelin is the trigger one step upstream. Daily Tesamorelin produces pulsatile GH release that preserves the hypothalamic-pituitary feedback loop and keeps IGF-1 in the physiological range. HGH produces flat, non-pulsatile GH elevation that bypasses the feedback loop and can push IGF-1 above the physiological range.

Can Tesamorelin be combined with Ipamorelin?

In non-label research settings, yes. Ipamorelin activates the ghrelin receptor and Tesamorelin activates the GHRH receptor, so the two produce summed pulses when injected together. Combination with CJC-1295 (a second GHRH agonist) adds little, because the receptor population saturates at Tesamorelin's reference dose.

Is Egrifta still commercially available?

Yes in the United States, marketed as Egrifta SV since 2019 with an improved reconstitution format. The original EU marketing authorization was voluntarily withdrawn by the sponsor in 2014 for commercial reasons. Research-chemical grade Tesamorelin remains available globally through laboratory suppliers.

Is Tesamorelin legal in Germany and the rest of the EU?

Tesamorelin is not an approved human medicine in the EU since 2014. The lyophilized peptide can be purchased for laboratory research under the standard research chemicals framework, but import, possession and use for human consumption is not authorized and may be prosecuted under the Arzneimittelgesetz (AMG) or equivalent national legislation. Individual country rules vary. This article covers research use only.

How should Tesamorelin be stored?

Lyophilized powder: refrigerated at 2 to 8 degrees Celsius, protected from light, in the original sealed vial, up to the manufacturer expiry. Reconstituted solution: refrigerated at 2 to 8 degrees Celsius, protected from light, maximum 14 days. Do not freeze at any stage, do not expose to ambient for more than brief periods, and discard any solution that develops particulates or discoloration.

Which BD MICRO-FINE size is appropriate?

A U100 insulin syringe of 0.5 mL capacity with a 30 gauge 8 mm needle is the standard choice for a 2 mg dose from a 10 mg + 2 mL reconstitution (which draws to 40 IU, within the 50 IU capacity of the barrel). If the reconstitution is 10 mg + 1 mL instead, the draw is only 20 IU and a 0.3 mL demi syringe works equally well.

What HPLC purity is acceptable?

Greater than 98 percent is the minimum for injectable research peptides, greater than 99 percent is preferable. The certificate of analysis should include the HPLC chromatogram, a mass spectrometry identity trace matching 5135.9 Da, and an endotoxin measurement below 5 EU per mg.

How long should a research cycle run?

Typical cycles run 12 to 26 weeks of daily dosing followed by at least 8 weeks of washout. The VAT-reduction effect is detectable at 8 weeks and plateaus between 26 and 52 weeks; the cognitive work published by Baker and colleagues used 20 weeks. Year-round continuous dosing has no additional efficacy data and gradually attenuates pulse amplitude via receptor desensitization.

Conclusion

Tesamorelin occupies a unique position in the peptide research landscape. It is the only GHRH analogue with a full Phase 3 dossier and an active FDA approval, its pharmacology is well-characterized across two decades of clinical work, and its dosing protocol is standardized at 2 mg subcutaneously once daily at bedtime. For researchers who already work with subcutaneous peptides, the operational footprint is modest: a 10 mg vial, bacteriostatic water, a U100 insulin syringe and a refrigerator. The math is unambiguous at either 10 mg + 1 mL (20 IU per 2 mg dose) or 10 mg + 2 mL (40 IU per 2 mg dose).

For research purposes only. Individual response, tolerability and IGF-1 kinetics vary, and any research program should include baseline and follow-up laboratory monitoring. The Retatrutide dosing guide covers the GLP-1/GIP/glucagon triagonist side of the metabolic peptide family for researchers working across multiple compounds.

Medical disclaimer

This blog post is for informational purposes only and is not a substitute for professional medical advice. Tesamorelin is an approved medicine in the United States for HIV-associated lipodystrophy only, is no longer approved as a medicine in the European Union, and all other uses are experimental. Use of Tesamorelin outside of approved clinical indications is not authorized in many jurisdictions.

All information regarding dosages, reconstitution protocols and applications is based on published peer-reviewed research, FDA label material and user reports, but may be inaccurate or incomplete. Individual responses, safety profiles and regulatory status can vary significantly between jurisdictions and between individuals.

Before using Tesamorelin or any other peptide, consult a qualified physician or healthcare professional. This article does not endorse off-label or illegal use of Tesamorelin. The author and parahealth assume no liability for side effects, injuries, or adverse events arising from the use of information discussed in this article.

For research purposes only. Not intended for human consumption.